Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 41Carcinoma, Renal Cell 32Neuroendocrine Tumors 15Neoplasms 12Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 8Carcinoma 7Tuberous Sclerosis 6Kidney Neoplasms 5Carcinoma, Hepatocellular 5Carcinoid Tumor 5Lymphoma 4Adenoma, Islet Cell 4Stomach Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Lymphangioleiomyomatosis 3Lung Neoplasms 3Colorectal Neoplasms 3Angiomyolipoma 3Adenocarcinoma 3von Hippel-Lindau Disease 2Triple Negative Breast Neoplasms 2Seizures 2Neuroectodermal Tumors, Primitive 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2

Interventions

ofatumumab 10ibrutinib 6Rituximab 5acalabrutinib 4Cyclophosphamide 3spebrutinib 2pirtobrutinib 2obinutuzumab 2navitoclax 2fludarabine phosphate 2Tablets 2Lenalidomide 2KW-2478 2Chlorambucil 2Antigens, CD19 2ARQ531 2venetoclax 1tirabrutinib 1pomalidomide 1pivalyloxymethyl butyrate 1immunotoxin HA22 1idelalisib 1idecabtagene vicleucel 1fludarabine 1dinaciclib 1bempegaldesleukin 1Vincristine 1Rabeprazole 1Prednisone 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, B-Cell × Everolimus × Clear all
NCT04305444 2025-01-08

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Zhejiang DTRM Biopharma

Phase 2 Terminated
55 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡